Tirzepatide

Tirzepatide is a 39-residue synthetic peptide built on the glucose-dependent insulinotropic polypeptide backbone rather than the GLP-1 backbone, which is the structural point that distinguishes it from single-incretin analogs. Alpha-aminoisobutyric acid occupies positions 2 and 13, blocking dipeptidyl peptidase-4 cleavage and constraining local backbone conformation. A C20 fatty diacid is conjugated at lysine 20 through a gamma-glutamate and two 2-aminoethoxy-acetic acid spacers, driving reversible albumin binding.

It engages two class B G-protein-coupled receptors at once. The pharmacology reported in the literature is notably imbalanced: it behaves as a full agonist at the GIP receptor while showing weaker, biased engagement at the GLP-1 receptor, with markedly reduced beta-arrestin recruitment relative to cAMP generation.

The in-vitro characterisation of this molecule rests on parallel cAMP accumulation assays in cell lines separately expressing the GIP and GLP-1 receptors, which is how the potency ratio between the two targets is established. Beta-arrestin recruitment assays run alongside these are what identified the biased signalling profile, since a compound can generate cAMP normally while failing to drive receptor internalisation.

Reduced beta-arrestin recruitment is associated in receptor pharmacology with slower homologous desensitisation, and that relationship is the mechanistic hypothesis most often examined in the reported work. Animal-model studies have addressed receptor occupancy, gastric emptying rate, and food intake in relation to signalling at both receptor populations.

Each lot is released against reversed-phase HPLC for purity and mass spectrometry for identity, reported on the lot-specific Certificate of Analysis. Two features of this sequence make the chromatography unusually load-bearing. The two alpha-aminoisobutyric acid residues are sterically hindered and couple inefficiently during solid-phase synthesis, so deletion sequences missing one of them are the characteristic impurity, and a single missing residue shifts mass only slightly on a 39-mer.

The acylation site requires separate confirmation for the same reason it does on any fatty-acylated sequence: misacylation at an alternative lysine produces a molecule of identical mass that mass spectrometry alone cannot distinguish. Peptide mapping after enzymatic digestion resolves it where chromatography alone does not.